Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

beta-catenin inhibitor FOG-001

A conformationally stabilized alpha-helical polypeptide and direct inhibitor of the oncogenic driver beta-catenin, with potential immunomodulating and antineoplastic activities. Upon administration, beta-catenin inhibitor FOG-001 penetrates into the cell where it targets and binds to beta-catenin, thereby preventing the interaction of beta-catenin with the transcriptional factor T-cell factor (TCF). This disrupts beta-catenin-dependent oncogenic signaling and prevents the transcription of Wnt target genes that regulate the proliferation, migration, invasion, and the metastatic potential of tumor cells, as well as genes regulating the immunosuppression of the tumor microenvironment (TME). Dysregulation of the Wnt/beta-catenin signaling pathway is found in a variety of tumors and drives oncogenesis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:beta-catenin antagonist FOG-001
helicon FOG-001
TCF-blocking beta-catenin inhibitor FOG-001
Code name:FOG 001
FOG-001
FOG001
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search